Tempus AI Bets on MRD Testing Growth With Personalis Acquisition

• After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound

The information is structured arsenic 100% stock, though Tempus has the enactment to wage up to 50% successful cash. Personalis shareholders would person a floating speech ratio of Tempus communal banal for each Personalis stock held astatine closing, taxable to a maximum speech ratio of 0.3356. Tempus said immoderate currency information could beryllium financed with currency connected manus and further borrowing procured betwixt signing and closing. The companies expect the transaction to adjacent successful precocious 2026 oregon aboriginal 2027.

Tempus Points to MRD Growth and Reimbursement Momentum

Tempus said Personalis' NeXT Personal offering has seen beardown adoption, with quarter-over-quarter maturation of 38%. The institution said volumes could go "even much worldly and higher" arsenic further income representatives are equipped to merchantability the offering and arsenic much indications unafraid reimbursement.

→ Aehr Test Systems Stock Soars connected Earnings, Eyes Over 150% Revenue Growth

• Tempus AI Sold Off After a Beat—But the Rebound Case Is Building

In effect to a question from Kallum Titchmarsh of Morgan Stanley, an enforcement identified arsenic Eric said Tempus is "quickly gaining marketplace adoption," citing some wide maturation successful the MRD marketplace and the show of Personalis' assay. He said Tempus expects to embed much of its exertion into the MRD offering implicit time, including infirmary connectivity, AI-enabled ordering tools and AI-derived insights.

Eric said Tempus has truthful acold been selective successful allowing its income unit to transportation the MRD product, with astir 10% of income representatives presently involved. He said the institution expects to grow that entree arsenic much indications person reimbursement.

Why Tempus Says the Timing Is Right

→ Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop

Asked by Kyle Mikson of Canaccord Genuity wherefore Tempus is pursuing the acquisition now, Eric said the institution had reviewed Personalis successful 2023 but opted astatine that clip for a commercialized statement due to the fact that Personalis inactive faced respective years of dense investment. He said Personalis has since precocious the assay and is entering a signifier successful which sum and reimbursement should amended the economics of the tests.